A Retinal Bet With Big-Pharma Muscle and Blackstone Financing
Johnson & Johnson (NYSE: JNJ) is putting substantial capital behind a straightforward proposition: better control of retinal disease, potentially with more time between treatments, would be worth bringing into its pharmaceutical portfolio. On…
A Funded Biotech With a Date Worth Watching
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) is approaching a consequential clinical milestone with something that makes the occasion considerably more interesting: enough financial breathing room to focus on the science. The company’s November…
AlloSure Kidney Data Excites, Dupixent Sales Surge and POTENTIAL Competitor, EP-104GI, Nears December EoE Catalyst
Biotechnology’s most persuasive growth stories are moving beyond laboratory promise and into financial statements, clinical evidence and approaching trial milestones. CareDx (NASDAQ: CDNA) reported third-quarter revenue growth…
With its 120-patient target reached, encouraging early durability data and a November investor calendar, Eupraxia Pharmaceuticals is building a more substantial case for long-acting drug delivery.
Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) is approaching the kind of stretch that can move a…
With 120 patients enrolled in its Phase 2b study, Eupraxia’s drug-delivery platform moves toward a consequential clinical test.
For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), the story is becoming less about recruiting patients and more about what their results might reveal.…
Wall Street Price targets of $16, $17 and $18 seem to underscore the potential for a long-acting treatment as December clinical data approach
Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) has received a timely vote of confidence from three research firms, with newly…
The Market’s Growth Engines Are Getting Physical
Wall Street has spent years rewarding promises around artificial intelligence, advanced medicine and space infrastructure. This week, the narrative acquired something investors usually appreciate even more: concrete evidence of execution. Bayer AG (OTC: BAYRY) is…
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose…
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…
The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…
